Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study of dolutegravir + rilpivirine versus continuing current antiretroviral regimen in virologically suppressed adults with HIV-1
NL-OMON47247Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at week 48. Started Jul 2015; status: active, not recruiting.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON47247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47247.